tiprankstipranks
Trending News
More News >
JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Japanese Market
Advertisement

JCR Pharmaceuticals Co., Ltd. (4552) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4552

JCR Pharmaceuticals Co., Ltd.

(4552)

Rating:56Neutral
Price Target:
¥707.00
▲(3.21%Upside)
The overall stock score for JCR Pharmaceuticals Co., Ltd. reflects significant financial challenges, including declining profitability and increasing debt levels. Despite this, the stock shows strong bullish momentum in technical analysis, which partially offsets the financial concerns. The negative P/E ratio highlights the current unprofitability, but the dividend yield provides some support to the valuation.

JCR Pharmaceuticals Co., Ltd. (4552) vs. iShares MSCI Japan ETF (EWJ)

JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model

Company DescriptionJCR Pharmaceuticals Co., Ltd. (4552) is a Japanese pharmaceutical company specializing in biopharmaceuticals and regenerative medicine. The company is involved in the development, manufacturing, and marketing of pharmaceuticals with a focus on rare diseases, enzyme replacement therapies, and regenerative treatments. JCR Pharmaceuticals is known for its innovative approaches in the biotechnology sector, leveraging its expertise in cell and gene therapies to address unmet medical needs globally.
How the Company Makes MoneyJCR Pharmaceuticals makes money primarily through the development and sale of its proprietary pharmaceutical products. The company's key revenue streams include the commercialization of enzyme replacement therapies for rare diseases and regenerative medicine products. JCR collaborates with global pharmaceutical companies and research institutions to expand its product offerings and access new markets. Additionally, the company licenses its technologies and intellectual properties to other entities, generating royalty income. Strategic partnerships and joint ventures also play a significant role in enhancing JCR's research capabilities and market reach, contributing to its financial growth.

JCR Pharmaceuticals Co., Ltd. Financial Statement Overview

Summary
JCR Pharmaceuticals Co., Ltd. faces significant financial challenges. The income statement shows declining profitability and revenue, with negative margins indicating operational inefficiencies. The balance sheet is stable but under pressure from increasing debt levels. Cash flow issues are apparent with negative operating and free cash flows, indicating liquidity constraints. Overall, the company needs to address revenue growth, cost management, and debt levels to improve its financial health.
Income Statement
45
Neutral
The income statement reflects significant volatility. Gross profit margins were generally strong in past years but have suffered recently due to declining revenue and increased costs. The net profit margin has turned negative in the latest year, indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in the most recent year. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.
Balance Sheet
55
Neutral
The balance sheet shows a stable equity base, but with a concerning rise in total debt, increasing the debt-to-equity ratio. Return on equity has turned negative due to recent net losses. However, the equity ratio remains healthy, indicating a strong asset base relative to liabilities. The financial structure suggests potential risks if the current trend of increasing debt continues.
Cash Flow
40
Negative
The cash flow statement highlights challenges with a negative free cash flow and operating cash flow in the latest period. The operating cash flow to net income ratio shows poor cash generation from operations, suggesting inefficiencies. The free cash flow has decreased significantly, raising concerns about the company's ability to fund operations and growth without external financing.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue33.07B42.87B34.34B51.08B30.09B
Gross Profit21.55B31.25B25.46B40.62B22.27B
EBITDA-2.88B10.53B6.97B21.88B10.18B
Net Income-4.76B5.51B3.77B14.51B6.89B
Balance Sheet
Total Assets104.86B102.23B94.94B97.13B73.78B
Cash, Cash Equivalents and Short-Term Investments13.20B18.76B13.28B30.98B26.26B
Total Debt38.10B23.30B22.80B18.10B18.10B
Total Liabilities57.42B45.75B42.52B46.05B35.23B
Stockholders Equity47.04B56.18B52.16B50.88B38.38B
Cash Flow
Free Cash Flow-15.37B7.22B-14.06B-2.04B2.81B
Operating Cash Flow-5.49B9.31B-5.50B9.29B10.34B
Investing Cash Flow-9.87B-2.69B-15.00B-3.25B-3.29B
Financing Cash Flow9.74B-2.03B1.95B-2.18B8.30B

JCR Pharmaceuticals Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price685.00
Price Trends
50DMA
556.98
Positive
100DMA
517.16
Positive
200DMA
563.19
Positive
Market Momentum
MACD
42.55
Negative
RSI
75.65
Negative
STOCH
88.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Positive. The current price of 685 is above the 20-day moving average (MA) of 603.20, above the 50-day MA of 556.98, and above the 200-day MA of 563.19, indicating a bullish trend. The MACD of 42.55 indicates Negative momentum. The RSI at 75.65 is Negative, neither overbought nor oversold. The STOCH value of 88.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4552.

JCR Pharmaceuticals Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
¥80.22B9.64
1.64%8.83%70.61%
76
Outperform
¥66.69B13.93
2.00%2.06%-32.48%
67
Neutral
€103.96B19.054.35%2.62%5.31%90.37%
65
Neutral
¥355.15B11.37-2.99%2.48%11.78%-10.17%
62
Neutral
$104.50B77.472.35%0.69%5.94%-45.43%
56
Neutral
¥84.77B
2.92%-22.86%-188.19%
43
Neutral
¥79.27B-3.36%87.83%75.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4552
JCR Pharmaceuticals Co., Ltd.
703.00
101.18
16.81%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,524.00
-122.79
-7.46%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,446.00
213.58
9.57%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,055.00
-325.67
-9.63%
JP:3341
Nihon Chouzai Co
3,380.00
1,888.64
126.64%
JP:4565
Sosei Group
876.00
-826.00
-48.53%

JCR Pharmaceuticals Co., Ltd. Corporate Events

JCR Pharmaceuticals Completes Treasury Stock Disposition for Compensation
Jul 25, 2025

JCR Pharmaceuticals Co., Ltd. announced the completion of payment procedures for the disposition of treasury stock as restricted stock compensation. This move, involving 111,000 shares of common stock at 518 yen per share, is part of a strategic initiative to align the interests of directors, executive officers, and employees with the company’s long-term goals, potentially enhancing its operational effectiveness and market position.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Treasury Stock Disposition for Incentive Plan
Jun 25, 2025

JCR Pharmaceuticals Co., Ltd. announced a plan to dispose of 111,000 shares of its treasury stock as part of a restricted stock compensation plan aimed at incentivizing its directors and employees. This initiative is designed to align the interests of the company’s leadership with those of its shareholders, promoting sustained corporate value enhancement and ensuring continued commitment from key personnel.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Strengthens Ties with MEDIPAL HOLDINGS for Global Expansion
Jun 25, 2025

JCR Pharmaceuticals Co., Ltd. has announced its relationship with MEDIPAL HOLDINGS CORPORATION, which is its largest shareholder with a 23.86% voting rights ownership. The companies have a business alliance to enhance corporate value and growth, leveraging MEDIPAL’s distribution strengths and JCR’s pharmaceutical R&D capabilities. Recent agreements between the two include exclusive negotiation rights for the global commercialization of JCR’s new drug candidates targeting ultra-rare lysosomal storage diseases, and licensing agreements for treatments like JR-471 and JR-446. These collaborations are expected to bolster JCR’s industry positioning and operational capabilities.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Gain on Deferred Income Taxes
May 14, 2025

JCR Pharmaceuticals Co., Ltd. has announced a recognition of gain on deferred income taxes for the fiscal year ended March 31, 2025, resulting in a corporate tax adjustment profit of 1,771 million yen. This adjustment reflects the company’s performance trends and careful review of deferred tax assets’ recoverability, impacting the consolidated financial results positively and demonstrating JCR’s strategic financial management.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Leadership Transition for 2026
May 13, 2025

JCR Pharmaceuticals has announced a leadership transition effective April 1, 2026, marking a generational shift as the company celebrates its 50th anniversary. Toru Ashida will become Chairman and Hiroyuki Sonoda will assume the role of President, while current Chairman, President, and CEO Shin Ashida will transition to Founder and Director. This change aims to strengthen the management structure and enhance long-term corporate value.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Reports Significant Financial Losses for FY2024
May 13, 2025

JCR Pharmaceuticals reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 22.9% and a net loss of 4,759 million yen. The company is undergoing changes, including the exclusion of Mycenax Biotech Inc. from its subsidiaries and adjustments in accounting policies, as it aims to improve its financial standing and operational efficiency in the coming fiscal year.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Consistent Dividend Distribution for 2025
May 13, 2025

JCR Pharmaceuticals Co., Ltd. announced the distribution of retained earnings as dividends, with a term-end dividend of 10.00 yen per share for the fiscal year ending March 31, 2025, matching the previous year’s dividend. This decision aligns with JCR’s policy of consistent profit distribution while maintaining reserves for new drug development and financial stability.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025